SCHEMBL15096236

SCHEMBL15096236

C=C(NCC(C)C)c1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 5/20 0.45
HTT P42858 2/20 0.45
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
EPHX2 P34913 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NAPRT Q6XQN6 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
ALOX12 P18054 1/20 0.41
GSK3B P49841 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
TOP2A P11388 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15096231 0.81 P2RX7 (0.44) ALDH1A1CYP1A2CYP2C19HTTKMT2A
SCHEMBL15096232 0.81 P2RX7 (0.44) ALDH1A1CYP1A2CYP2C19KDM4EHTT
SCHEMBL19930565 0.81 ALDH1A1 (0.51) ALDH1A1CYP1A2CYP2C19KDM4EHTT
SCHEMBL4260290 0.81 KMT2A (0.59) ALDH1A1KDM4EHTTEPHX2SMN1; SMN2
SCHEMBL17108526 0.80 ALDH1A1 (0.46) ALDH1A1CYP1A2CYP2C19KDM4EHTT
SCHEMBL21707783 0.78 CES2 (0.45) ALDH1A1KDM4EHTTCES2CES1
SCHEMBL16429529 0.77 ALDH1A1 (0.50) ALDH1A1CYP1A2CYP2C19KDM4EHTT
SCHEMBL24141751 0.76 ALDH1A1 (0.46) ALDH1A1CYP1A2CYP2C19KDM4EHTT
SCHEMBL31431959 0.74 ALDH1A1 (0.52) ALDH1A1KDM4EHTTCES2CES1
SCHEMBL20751787 0.73 CES2 (0.48) ALDH1A1KDM4ECES2CES1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975232-B2 Macrocyclic kinase inhibitors and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-03-10 US disclosed
US-20130178429-A1 MACROCYCLIC KINASE INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178429-A1 MACROCYCLIC KINASE INHIBITORS AND USES THEREOF MAP3K20, MAP3K11, MAP3K1 ALDH1A1 3932/4885CYP1A2 2252/4885CYP2C19 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.